Section Arrow
NKTR.NASDAQ
- Nektar Therapeutics
Quotes are at least 15-min delayed:2024/09/21 00:11 EDT
Last
 1.29
+0.02 (+1.57%)
Day High 
1.315 
Prev. Close
1.27 
1-M High
1.38 
Volume 
2.40M 
Bid
1.23
Ask
1.35
Day Low
1.23 
Open
1.25 
1-M Low
1.08 
Market Cap 
233.78M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.25 
20-SMA 1.25 
50-SMA 1.28 
52-W High 1.928 
52-W Low 0.4126 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/-1.01
Enterprise Value
332.30M
Balance Sheet
Book Value Per Share
0.43
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
90.12M
Operating Revenue Per Share
0.48
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CEROCERo Therapeutics Holdings0.115+0.028+32.18%-- 
NBYNovaBay Pharmaceuticals0.74+0.2431+48.92%-- 
ADMAADMA Biologics19.98+0.24+1.22%141PE
ROIVRoivant Sciences Ltd11.97+0.05+0.42%2.08PE
TGTXTG Therapeutics24.65-0.63-2.49%37.18PE
Quotes are at least 15-min delayed:2024/09/21 00:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people.The group derives revenue from the United States and the Rest of the World.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.